Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
457 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04205630 | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | completed | Phase 2 | 64 | Byondis B.V.INDUSTRY | 7 | May 30, 2024 | clinicaltrials |
| NCT00110110 | Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma | unknown | Phase 2 | 71 | The Hospital for Sick ChildrenOTHER | 4 | Apr 17, 2024 | clinicaltrials |
| NCT06336395 |
| Ma-Spore ALL 2020 Study |
| recruiting |
| Phase 2 |
| 500 |
| National University Hospital, SingaporeOTHER |
| 2 |
| Mar 28, 2024 |
| clinicaltrials |
| NCT02414139 | Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) | completed | Phase 2 | 373 | Novartis PharmaceuticalsINDUSTRY | 20 | Mar 20, 2024 | clinicaltrials |
| NCT01543698 | A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 189 | PfizerINDUSTRY | 9 | Mar 13, 2024 | clinicaltrials |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | terminated | Phase 2 | 63 | Debiopharm International SAINDUSTRY | 23 | Feb 7, 2024 | clinicaltrials |
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
| NCT02608268 | Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 252 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 6, 2023 | clinicaltrials |
| NCT00355238 | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer | completed | Phase 2 | 137 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 1, 2023 | clinicaltrials |
| NCT03093831 | Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma | terminated | Phase 2 | 5 | National Cancer Centre, SingaporeOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01506856 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial(iPocc) | completed | Phase 2 / Phase 3 | 655 | Gynecologic Oncology Trial & Investigation ConsortiumNETWORK | 6 | Sep 15, 2023 | clinicaltrials |
| NCT03759093 | CURATE.AI Optimized Modulation for Multiple Myeloma | unknown | Phase 2 / Phase 3 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | terminated | Phase 1 / Phase 2 | 14 | Cullinan Therapeutics Inc.INDUSTRY | 5 | Aug 15, 2023 | clinicaltrials |
| NCT00245154 | Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 296 | NCIC Clinical Trials GroupNETWORK | 6 | Aug 4, 2023 | clinicaltrials |
| NCT03695744 | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma | unknown | Phase 2 | 27 | Singapore General HospitalOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02365441 | A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)(ALT GIST) | unknown | Phase 2 | 78 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Jul 7, 2023 | clinicaltrials |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | terminated | Phase 2 | 143 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Jul 3, 2023 | clinicaltrials |
| NCT01104155 | Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 123 | Eisai Inc.INDUSTRY | 7 | Jun 22, 2023 | clinicaltrials |
| NCT02335944 | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | terminated | Phase 1 / Phase 2 | 177 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 18, 2023 | clinicaltrials |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | Dracen Pharmaceuticals, Inc.INDUSTRY | 5 | Jun 12, 2023 | clinicaltrials |
| NCT02935634 | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer(FRACTION-GC) | completed | Phase 2 | 190 | Bristol-Myers SquibbINDUSTRY | 9 | Jun 9, 2023 | clinicaltrials |
| NCT04522284 | PRECISE CURATE.AI Pilot Clinical Trial | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05429905 | Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia | unknown | Phase 1 / Phase 2 | 48 | KK Women's and Children's HospitalOTHER_GOV | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05648019 | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | recruiting | Phase 2 | 40 | KK Women's and Children's HospitalOTHER_GOV | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05175235 | Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements | unknown | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT00702481 | Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer | completed | Phase 2 | 32 | National Cancer Centre, SingaporeOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03386721 | Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors | terminated | Phase 2 | 256 | Hoffmann-La RocheINDUSTRY | 15 | Feb 21, 2023 | clinicaltrials |
| NCT03499899 | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | completed | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 17 | Jan 30, 2023 | clinicaltrials |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | terminated | Phase 2 | 16 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT01625286 | Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients(BEECH) | completed | Phase 1 / Phase 2 | 148 | AstraZenecaINDUSTRY | 11 | Jan 18, 2023 | clinicaltrials |
| NCT01982955 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | completed | Phase 1 / Phase 2 | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Nov 8, 2022 | clinicaltrials |
| NCT00997906 | Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC | unknown | Phase 2 / Phase 3 | 172 | National Cancer Centre, SingaporeOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT04909515 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. | withdrawn | Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 4 | Sep 1, 2022 | clinicaltrials |
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 154 | Hoosier Cancer Research NetworkOTHER | 3 | Jul 11, 2022 | clinicaltrials |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | withdrawn | Phase 1 / Phase 2 | 0 | Lion TCR Pte. Ltd.INDUSTRY | 2 | Jun 30, 2022 | clinicaltrials |
| NCT03091491 | Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer | terminated | Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT02736305 | Use of Regorafenib in Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 21 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-01) | terminated | Phase 1 / Phase 2 | 13 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT05236608 | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC(ADIVO Lung) | unknown | Phase 1 / Phase 2 | 53 | National University Hospital, SingaporeOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT01896531 | A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 153 | Genentech, Inc.INDUSTRY | 11 | Mar 2, 2022 | clinicaltrials |
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | terminated | Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 8 | Feb 28, 2022 | clinicaltrials |
| NCT03130790 | Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | completed | Phase 2 / Phase 3 | 52 | ASLAN PharmaceuticalsOTHER | 8 | Feb 15, 2022 | clinicaltrials |
| NCT02460224 | Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 / Phase 2 | 490 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 10, 2022 | clinicaltrials |
| NCT02605967 | Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 122 | Novartis PharmaceuticalsINDUSTRY | 7 | Feb 10, 2022 | clinicaltrials |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 3 | Jan 26, 2022 | clinicaltrials |
| NCT02038946 | Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) | completed | Phase 2 | 116 | Bristol-Myers SquibbINDUSTRY | 12 | Jan 4, 2022 | clinicaltrials |
| NCT00462943 | Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | completed | Phase 2 | 100 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Dec 28, 2021 | clinicaltrials |
| NCT02857426 | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)(CheckMate 647) | completed | Phase 2 | 66 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials